Novo Nordisk A/S (NOV XETRA) stock market data APIs
€39.4909
1.1(2.8%)
as of May 6, 2026
Try our APIs with
free plan!
Novo Nordisk A/S Financial Data Overview
Price chart is built with
Anychart
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Prev. Close
39.4909
Open
40.5895
High
41.7466
Low
39.1432
52 wk Range
29.5655-68.3478
Market Cap
182 113 M
P/E Ratio
13.3344
Shares Outstanding
3 359 M
Revenue
309 064 M
Dividends (Yield)
0.3062
Beta
0.348
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Novo Nordisk A/S data using free add-ons & libraries
Get Novo Nordisk A/S Fundamental Data
Novo Nordisk A/S Fundamental data includes:
- Net Revenue: 309 064 M
- EBITDA: 153 295 M
- Earnings Per Share: 3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-06
- EPS/Forecast: 5.46
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Novo Nordisk A/S News
New
Novo Nordisk Pops After Leapfrogging Eli Lilly With An Obesity Pill
Novo Nordisk stock popped Tuesday on reports it's asked the FDA to approve its weight-loss pill, an oral version of Wegovy. Continue Reading View Comments
Novo Nordisk (NVO) Is a Good Short-Term Pick, Wealth Manager Says
Novo Nordisk (NVO), which develops weight-loss drugs, looks poised to perform well over the short term, Rebecca Walser, the founder and principal of Walser Wealth Management, told Schwab Network recen...
Novo shares down on Eli Lilly’s positive obesity pill data
Investing.com -- Novo Nordisk (NYSE:NVO) shares sank more than 7% in Copenhagen after Eli Lilly (NYSE:LLY) released promising trial results for its experimental obesity pill, orforglipron, which showe...
Novo Nordisk Drops on Weight-Loss Study by Rival Lilly
Novo Nordisk slumped after a pill from rival Eli Lilly helped patients shed weight and control blood sugar about as well as its injected blockbuster Ozempic. Bloomberg Intelligence's Sam Fazeli explains. View Comments
Get Novo Nordisk A/S fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
